High density lipoproteins-based therapies for cardiovascular disease

Journal of Cardiovascular Disease Research

Volumn 1, Issue 3, 2010, Pages 99-103

  Gao, Xuan ^a   Yuan, Shujun ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; drug development; High density lipoprotein; reverse cholesterol transport

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; D4F; DALCETRAPIB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT; LIVER X RECEPTOR; NICOTINIC ACID; PEPTIDE; TORCETRAPIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; FLUSHING; HEART PROTECTION; HUMAN; LIPID COMPOSITION; LIVER TOXICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT;

EID: 79953034517     PISSN: 09753583     EISSN: 09762833     Source Type: Journal    
DOI: 10.4103/0975-3583.70898     Document Type: Review

References (48)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76. (Pubitemid 27192468)
2. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High - Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86:19L-22.
3. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. (Pubitemid 28213628)
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431-8.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
7. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
8. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008;54:788-800. (Pubitemid 351671595)
9. Wlodawer A, Segrest JP, Chung BH, Chiovetti R Jr, Weinstein JN. High-density lipoprotein recombinants: Evidence for a bicycle tire micelle structure obtained by neutron scattering and electron microscopy. FEBS Lett 1979;104:231-5.
10. Shipley GG, Atkinson D, Scanu AM. Small-angle x-ray scattering of human serum high-density lipoproteins. J Supramol Struct 1972;1:98-104.
11. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-74. (Pubitemid 44394906)
12. Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: Fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 2006;445:245-55. (Pubitemid 43082217)
13. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55. (Pubitemid 351194062)
14. de Beer MC, Durbin DM, Cai L, Jonas A, de Beer FC, Van der Westhuyzen DR. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J Lipid Res 2001;42:309-13. (Pubitemid 32206844)
15. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
16. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-32. (Pubitemid 40962099)
17. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004;101:9774-9. (Pubitemid 38869312)
18. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999;40:345-53. (Pubitemid 29069810)
19. Furnkranz A, Schober A, Bochkov VN, Bashtrykov P, Kronke G, Kadl A, et al. Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb Vasc Biol 2005;25:633-8. (Pubitemid 40315690)
20. Chapman MJ. Are the effects of statins on HDL-cholesterol clinically relevant? Eur Heart J 2004;6 (suppl C): C58-63. (Pubitemid 38844954)
21. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: Current and future therapies. J Am Coll Cardiol 2010;55:1283-99.
22. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511. (Pubitemid 29372891)
23. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
24. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98. (Pubitemid 20364735)
25. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Pubitemid 33126837)
26. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7. (Pubitemid 39612564)
27. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50. (Pubitemid 44789989)
28. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955;54:558-9.
29. Soudijn W, van Wijngaarden I, Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 2007; 27:417-33. (Pubitemid 46668940)
30. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005;4:193-205. (Pubitemid 40372554)
31. Sood A, Arora R. Mechanisms of flushing due to niacin and abolition of these effects. J Clin Hypertens (Greenwich) 2009;11:685-9.
32. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992;34:165-8.
33. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8. (Pubitemid 29362514)
34. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45. (Pubitemid 17147964)
35. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61.
36. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, et al. Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr Opin Lipidol 2006;17:440-4. (Pubitemid 44079483)
37. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 2009;50:S201-6.
38. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: Individual patient meta-analysis of 13,677 subjects. Circulation 2005;111:278-87. (Pubitemid 40165333)
39. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. (Pubitemid 350146106)
40. Connelly MA, Parry TJ, Giardino Edward C, Huang Z, Cheung W, Chen C, et al. Torcetrapib Produces Endothelial Dysfunction Independent of Cholesteryl Ester Transfer Protein Inhibition. J Cardiovasc. Pharmacol 2010;55:459-568.
41. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8. (Pubitemid 40544314)
42. Krishna R, Anderson MS, Bergman A J, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14. (Pubitemid 350192656)
43. Pirillo A, Uboldi P, Pappalardo G, Kuhn H, Catapano AL. Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. Cardiovasc Res 2007;75:566-74. (Pubitemid 47080967)
44. Gao X, Jayaraman S, Gursky O. Mild oxidation promotes and advanced oxidation impairs remodeling of human high-density lipoprotein in vitro. J Mol Biol 2008;376:997-1007.
45. Gao X, Yuan S, Jayaraman S, Gursky O. Differential stability of high-density lipoprotein subclasses: Effects of particle size and protein composition. J Mol Biol 2009;387:628-38.
46. Guha M, Gao X, Jayaraman S, Gursky O. Correlation of structural stability with functional remodeling of high-density lipoproteins: The importance of being disordered. Biochemistry 2008;47:11393-7.
47. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006;3:e22.
48. Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004;45:2161-73. (Pubitemid 39602963)